U.S. Markets closed

Shareholder Alert: Robbins Arroyo LLP is Investigating Surface Oncology, Inc. (SURF)

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Shareholder rights law firm Robbins Arroyo LLP informs shareholders that it is investigating Surface Oncology (SURF) for potential violations of federal securities laws pursuant to its April 2018 initial public offering ("IPO"). Surface Oncology completed its IPO on April 23, 2018, offering shares at $15.00. Since its IPO, Surface Oncology's stock has plummeted, and currently trades at $2.06, or less than 85% of its IPO price. Surface Oncology is a clinical-stage immune-oncology company that engages in the development of cancer therapies.

If you suffered a loss as a result of Surface Oncology's misconduct, click here.

Surface Oncology, Inc. (SURF) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
LKandinov@robbinsarroyo.com
Shareholder Information Form

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190806005995/en/